Lilly’s Jaypirca (pirtobrutinib) Shows Significant Progression-Free Survival Benefit in…
Eli Lilly and Company announced positive topline results from the Phase 3 BRUIN CLL-313 clinical trial evaluating Jaypirca (pirtobrutinib) in treatment-naïve patients with chronic…
Read More...
Read More...
